Vendor Intelligence Report: Peptide Partners

Executive summary

Across 77 Finnrick lab tests, Peptide Partners shows a 68% overall pass rate, with 52 pass and 24 fail. The catalog is not evenly reliable: Retatrutide is the standout, Ipamorelin also reads favorable, while TB-500 and CJC-1295 are the products a buyer should treat as weak unless the current batch has unusually strong proof. Under stricter grading, the weaker products lose more ground; identity and purity are generally not the central issue, but fill and label-claim variance are.

On the business side, Peptide Partners is more traceable than the usual gray-market storefront. Its policies name Pirsek Technologies LLC and Wyoming law, public media identify Zak David at the operator level, and the site publishes batch COAs from named labs. The unresolved gap is narrower but material: the investigation did not independently confirm the Wyoming filing, and the Sarasota footprint should not be read as a verified facility.

The digital trail points to a young but professional operation: a March 2025 Shopify redirect, current WooCommerce storefront, AWS/Route 53 infrastructure, Google Workspace email, and Atlassian verification records. Reputation is harder to cleanly score. A removed Trustpilot profile, visible /ref/ URLs, coupon-code pages, and X promoter posts mean buyer-facing praise needs to be separated from authentication and batch evidence.

Inside the full report:

• Appendix A with per-product pass/fail rates, methodology-divergence charts, and product trajectories for all 7 products
• Dosage-variance analysis showing the batch-level label-claim deviations behind the safety risk
• Corporate identity trail linking Peptide Partners, Pirsek Technologies LLC, Wyoming policy disclosures, and the unresolved registry check
• Founder and staff attribution using media, SEC, A4M, and LinkedIn records
• Infrastructure and storefront history, including the Shopify redirect, WooCommerce build, AWS DNS/CDN, and Atlassian records
• Referral, coupon, Trustpilot, and competitor-dispute review of the public reputation ecosystem

Risk assessment

• Product-specific fill and batch-consistency risk — high: Highest concern is product-specific: TB-500 30.76% and CJC-1295 36.47% are fail-heavy; BPC-157 52.08% and Tesamorelin 50.26% remain marginal, with documented label deviations including CJC-1295 +62% and BPC-157 +30%.
• Affiliate-promotion and disclosure risk — medium: Scan found 21 promoter/coupon records and 20 code/link placements; referral-carrying disclosure was 3 yes /17 no, so buyer-facing praise should be treated as advertising.
• Manufacturer-disclosure risk — medium: Media/third-party records indicate China-sourced raw materials, but no primary manufacturer or import chain is named; lab COAs mitigate but do not replace upstream source visibility.
• Regulatory-continuity risk — medium: RUO vendor sells unapproved compounds including retatrutide; no FDA warning surfaced, but enforcement or payment-processing disruption remains plausible.
• Corporate-registration verification risk — medium: Pirsek Technologies LLC is self-disclosed in policies, but Wyoming SOS, Florida Sunbiz and OpenCorporates searches did not confirm the filing.
• Review-integrity risk — medium: Trustpilot profile reportedly had 83 reviews at 4.4 stars before removal; cause is unconfirmed and the review ecosystem overlaps with affiliate promotion.
• Brand-authenticity and copycat-control risk — medium: No typosquat was confirmed, but vendor's logo-copying allegation and many unofficial coupon/referral pages surfaced without an authorized-channel or reseller list.